PT2598533T - Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada - Google Patents

Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada

Info

Publication number: PT2598533T
Authority: PT; Portugal
Prior art keywords: compositions; fusion proteins; human protein; protein fragments; natural human
Prior art date: 2010-07-28

Application number

PT11813204T

Other languages

English (en)

Inventor

David S C/O Gliknik Inc Block

Henrik C/O Gliknik Inc Olsen

Original Assignee

Gliknik Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-28

Filing date

2011-07-28

Publication date

2019-05-08

2011-07-28 Application filed by Gliknik Inc filed Critical Gliknik Inc

2019-05-08 Publication of PT2598533T publication Critical patent/PT2598533T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT11813204T 2010-07-28 2011-07-28 Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada PT2598533T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36846510P	2010-07-28	2010-07-28

Publications (1)

Publication Number	Publication Date
PT2598533T true PT2598533T (pt)	2019-05-08

Family

ID=45530725

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT11813204T PT2598533T (pt)	2010-07-28	2011-07-28	Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada

Country Status (21)

Country	Link
US (4)	US20130156765A1 (pt)
EP (2)	EP2598533B1 (pt)
JP (2)	JP5826270B2 (pt)
KR (3)	KR20200111213A (pt)
CN (2)	CN103154036B (pt)
AR (1)	AR082404A1 (pt)
AU (1)	AU2011282579B2 (pt)
BR (1)	BR112013002074B1 (pt)
CA (2)	CA2902942C (pt)
DK (1)	DK2598533T3 (pt)
ES (1)	ES2719623T3 (pt)
HR (1)	HRP20190652T1 (pt)
HU (1)	HUE044869T2 (pt)
IL (3)	IL224427A (pt)
MX (3)	MX347343B (pt)
PL (1)	PL2598533T3 (pt)
PT (1)	PT2598533T (pt)
SI (1)	SI2598533T1 (pt)
TR (1)	TR201906652T4 (pt)
TW (2)	TWI588157B (pt)
WO (1)	WO2012016073A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107011445B (zh)	2007-06-01	2021-06-29	马里兰大学巴尔的摩分校	免疫球蛋白恒定区Fc受体结合剂
WO2010065578A2 (en) *	2008-12-04	2010-06-10	Leukosight Inc.	POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
PT2598533T (pt)	2010-07-28	2019-05-08	Gliknik Inc	Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
KR20150058236A (ko) *	2012-08-20	2015-05-28	글리크닉 인코포레이티드	항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
US20150218236A1 (en) *	2012-10-17	2015-08-06	Liverpool School Of Tropical Medicine	Immunomodulatory proteins
WO2014168715A1 (en) *	2013-04-08	2014-10-16	R-Pharm Overseas, Inc.	B7 ligands/cd20 inhibitor composition and use thereof
WO2015069745A2 (en) *	2013-11-05	2015-05-14	The Board Of Regents Of The University Of Texas System	Tumors expressing igg1 fc induce robust cd8 cell responses
EP3071599A4 (en) *	2013-11-18	2017-07-12	University of Maryland, Baltimore	Hyper-glycosylated antibodies with selective fc receptor binding
KR102452173B1 (ko) *	2013-12-24	2022-10-17	더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템	Fcrn 길항제 및 사용방법
CA2935960C (en)	2014-01-08	2023-01-10	Bart Lipkens	Acoustophoresis device with dual acoustophoretic chamber
CN106068274A (zh)	2014-03-05	2016-11-02	Ucb生物制药私人有限公司	多聚体Fc蛋白
EP3137506B1 (en)	2014-05-02	2023-08-30	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered fc constructs
EP3265131A1 (en) *	2015-03-05	2018-01-10	UCB Biopharma SPRL	Polymeric fc proteins and methods of screening to alter their functional characteristics
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
JP6937737B2 (ja)	2015-07-24	2021-09-22	グリックニックインコーポレイテッド	改良された補体結合を有する高次多量体化免疫グロブリンｆｃ組成物を作製するためのヒトタンパク質断片の融合タンパク質
CN109312000A (zh)	2016-03-30	2019-02-05	Ab生物科学有限公司	重组静脉内免疫球蛋白(rIVIG)组合物及其生产和使用方法
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
US11623964B2 (en)	2016-05-23	2023-04-11	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered Fc constructs
CA3026420A1 (en)	2016-06-07	2017-12-14	Gliknik Inc.	Cysteine-optimized stradomers
EP3487534A4 (en) *	2016-07-22	2020-03-25	Gliknik Inc.	FUSION PROTEINS FROM HUMAN PROTEIN FRAGMENTS FOR THE PRODUCTION OF MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH INCREASED FC RECEPTOR BINDING
AU2017371182B2 (en) *	2016-12-09	2024-03-28	Gliknik Inc.	Methods of treating inflammatory disorders with multivalent Fc compounds
PE20191354A1 (es) *	2016-12-09	2019-10-01	Gliknik Inc	Optimizacion de fabricacion de gl-2045, un stradomer multimerizante
CN110650748B (zh)	2017-01-06	2024-01-02	动量制药公司	与经工程改造的Fc构建体相关的组合物和方法
CN112004550A (zh)	2017-12-14	2020-11-27	康诺贝林伦瑙有限公司	用于治疗视神经脊髓炎的重组IgG Fc多聚体
WO2019118921A1 (en)	2017-12-14	2019-06-20	Flodesign Sonics, Inc.	Acoustic transducer drive and controller
CN114401985A (zh)	2019-09-13	2022-04-26	康诺贝林伦瑙有限公司	用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体
AU2021297998A1 (en) *	2020-06-25	2022-12-15	Gliknik Inc.	ACE2-Fc fusion proteins and methods of use
KR20230061710A (ko) *	2021-10-29	2023-05-09	주식회사 이뮤노로지컬디자이닝랩	Cadm1을 인식하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6004781A (en)	1988-01-22	1999-12-21	The General Hospital Corporation	Nucleic acid encoding Ig-CD4 fusion proteins
GB8824869D0 (en)	1988-10-24	1988-11-30	Stevenson G T	Synthetic antibody
US5681566A (en)	1988-10-24	1997-10-28	3I Research Exploitation Limited	Antibody conjugates with two or more covalently linked FC regions
US5336616A (en)	1990-09-12	1994-08-09	Lifecell Corporation	Method for processing and preserving collagen-based tissues for transplantation
ES2109362T3 (es)	1991-06-21	1998-01-16	Univ Cincinnati	Unas proteinas administrables oralmente y metodo para hacerlas.
IL102915A (en)	1992-01-19	2005-12-18	Yeda Res & Dev	Soluble ldl receptor and its preparation
JPH08503125A (ja)	1992-08-07	1996-04-09	プロジェニクス・ファーマスーティカルス・インコーポレーテッド	非ペプチジル成分と複合化されたＣＤ４−ガンマ２およびＣＤ４−ＩｇＧ２免疫複合体、並びにその使用
WO1994015640A1 (en)	1993-01-12	1994-07-21	Anthony George Gristina	Methods and compositions for the direct concentrated delivery of passive immunity
US5877396A (en)	1993-04-23	1999-03-02	Sloan Kettering Institute For Cancer Research	Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US20020147326A1 (en)	1996-06-14	2002-10-10	Smithkline Beecham Corporation	Hexameric fusion proteins and uses therefor
EP1082137A4 (en)	1998-05-06	2004-05-19	Univ Temple	REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
US7250494B2 (en)	1998-06-15	2007-07-31	Biosynexus Incorporated	Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US6933326B1 (en)	1998-06-19	2005-08-23	Lifecell Coporation	Particulate acellular tissue matrix
EP1105427A2 (en)	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
US7087411B2 (en)	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
ES2391760T3 (es)	2000-01-03	2012-11-29	The Trustees Of The University Of Pennsylvania	Proteínas quiméricas novedosas y métodos para usar las mismas
ATE359812T1 (de)	2001-01-12	2007-05-15	Becton Dickinson Co	Intrinsische fluoreszierende, selbstmultimerisierende mhc-fusionsproteine und deren komplexe
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
EP2316951A1 (en)	2001-01-17	2011-05-04	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
PL206701B1 (pl)	2001-03-07	2010-09-30	Merck Patent Gmbh	Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US7511121B2 (en)	2001-03-09	2009-03-31	Arnason Barry G W	Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
US7282556B2 (en)	2001-05-15	2007-10-16	Emory University	Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
KR100453877B1 (ko)	2001-07-26	2004-10-20	메덱스젠 주식회사	연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ATE335770T1 (de)	2001-12-18	2006-09-15	Dow Corning Toray Silicone	Photohärtbare organische polymerzusammensetzung
AU2003217912A1 (en) *	2002-03-01	2003-09-16	Xencor	Antibody optimization
JP2008522583A (ja)	2002-06-14	2008-07-03	セントカー・インコーポレーテツド	修飾“ｓ”抗体
EP2292259A3 (en)	2002-11-15	2011-03-23	MUSC Foundation For Research Development	Complement receptor 2 targeted complement modulators
CA2512974A1 (en)	2003-01-13	2004-07-29	Macrogenics, Inc.	Soluble fc.gamma.r fusion proteins and methods of use thereof
ATE438662T1 (de)	2003-03-26	2009-08-15	Apogenix Gmbh	Verbesserte fc-fusionsproteine
US7348004B2 (en)	2003-05-06	2008-03-25	Syntonix Pharmaceuticals, Inc.	Immunoglobulin chimeric monomer-dimer hybrids
EP1635872A4 (en)	2003-05-30	2008-01-02	Alexion Pharma Inc	ANTIBODIES AND FUSION PROTEINS COMPRISING MODIFIED CONSTANT REGIONS
WO2005005604A2 (en)	2003-06-30	2005-01-20	Centocor, Inc.	Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
AU2004321500A1 (en)	2003-09-29	2006-05-11	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Immunoglobulins with potent and broad antiviral activity
DK2239273T3 (da)	2003-11-13	2013-12-09	Hanmi Science Co Ltd	Farmaceutisk sammensætning, der omfatter en immunoglobulin Fc-region som en bærer
EP1697520A2 (en)	2003-12-22	2006-09-06	Xencor, Inc.	Fc polypeptides with novel fc ligand binding sites
WO2005089503A2 (en)	2004-03-19	2005-09-29	Progenics Pharmaceuticals, Inc.	Cd4-igg2 formulations
WO2006008739A2 (en)	2004-07-19	2006-01-26	Elutex Ltd.	Modified conductive surfaces having active substances attached thereto
WO2006031994A2 (en)	2004-09-14	2006-03-23	Xencor, Inc.	Monomeric immunoglobulin fc domains
EP1824979A2 (en)	2004-12-10	2007-08-29	Trigen GmbH	Methods, products and uses involving platelets and/or the vasculature
WO2006113889A2 (en)	2005-04-19	2006-10-26	University Of Maryland	Compositions and methods for modulating interleukin-10
AU2006244885B2 (en)	2005-05-09	2011-03-31	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
US7968316B2 (en)	2005-08-16	2011-06-28	Hanmi Holdings Co., Ltd.	Method for the mass production of immunoglobulin Fc region deleted initial methionine residues
US7666622B2 (en)	2005-10-19	2010-02-23	Regeneron Pharmaceuticals, Inc.	Monomeric self-associating fusion polypeptides and therapeutic uses thereof
EP1991578A2 (en)	2006-02-17	2008-11-19	Rappaport Family Institute For Research in the Medical Sciences	Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
ES2602439T3 (es)	2006-03-03	2017-02-21	The Chemo-Sero-Therapeutic Research Institute	Anticuerpo modificado con bioactividad mejorada
EP3805269A1 (en)	2006-06-12	2021-04-14	Aptevo Research and Development LLC	Single-chain multivalent binding proteins with effector function
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
GB0614780D0 (en)	2006-07-25	2006-09-06	Ucb Sa	Biological products
US20080260738A1 (en)	2007-04-18	2008-10-23	Moore Margaret D	Single chain fc, methods of making and methods of treatment
RS53302B (en)	2007-05-11	2014-08-29	Alexion Pharma Holding	BONE-Focused Alkaline Phosphatase, Supplies, and Methods of Use
CN101802197A (zh)	2007-05-14	2010-08-11	比奥根艾迪克Ma公司	单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
AU2008260498B2 (en) *	2007-05-30	2012-11-29	Xencor, Inc.	Methods and compositions for inhibiting CD32b expressing cells
CN107011445B (zh)	2007-06-01	2021-06-29	马里兰大学巴尔的摩分校	免疫球蛋白恒定区Fc受体结合剂
JP5706688B2 (ja)	2007-06-14	2015-04-22	ギャラクティカファーマシューティカルズ，インク．	Ｒａｇｅ融合タンパク質
AU2008302111B2 (en)	2007-09-21	2014-04-24	The Regents Of The University Of California	Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20090104210A1 (en)	2007-10-17	2009-04-23	Tota Michael R	Peptide compounds for treating obesity and insulin resistance
PL2222697T3 (pl)	2007-11-01	2013-05-31	Astellas Pharma Inc	Immunosupresyjne polipeptydy i kwasy nukleinowe
WO2010065578A2 (en)	2008-12-04	2010-06-10	Leukosight Inc.	POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
KR101808751B1 (ko)	2009-11-13	2017-12-13	그리폴스 테라퓨틱스 인코포레이티드	폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
GB0922209D0 (en)	2009-12-18	2010-02-03	Univ Nottingham	Proteins, nucleic acid molecules and compositions
CN103068399A (zh)	2010-06-30	2013-04-24	卡姆普根有限公司	用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的c1orf32
AU2015200330B2 (en)	2010-07-28	2016-10-27	Gliknik Inc.	Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
PT2598533T (pt)	2010-07-28	2019-05-08	Gliknik Inc	Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada
JP2015506372A (ja)	2012-01-27	2015-03-02	グリックニックインコーポレイテッド	ＩｇＧ２ヒンジドメインを含む融合タンパク質
KR20150058236A (ko)	2012-08-20	2015-05-28	글리크닉 인코포레이티드	항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
US20180282424A1 (en)	2014-11-06	2018-10-04	Gliknik Inc.	Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose
JP6937737B2 (ja)	2015-07-24	2021-09-22	グリックニックインコーポレイテッド	改良された補体結合を有する高次多量体化免疫グロブリンｆｃ組成物を作製するためのヒトタンパク質断片の融合タンパク質
PE20190209A1 (es)	2016-04-04	2019-02-07	Bioverativ Usa Inc	Anticuerpos anti-factor bb del complemento y uso de estos
CA3026420A1 (en)	2016-06-07	2017-12-14	Gliknik Inc.	Cysteine-optimized stradomers
AU2017371182B2 (en)	2016-12-09	2024-03-28	Gliknik Inc.	Methods of treating inflammatory disorders with multivalent Fc compounds

2011
- 2011-07-28 PT PT11813204T patent/PT2598533T/pt unknown
- 2011-07-28 DK DK11813204.2T patent/DK2598533T3/en active
- 2011-07-28 WO PCT/US2011/045768 patent/WO2012016073A2/en active Application Filing
- 2011-07-28 PL PL11813204T patent/PL2598533T3/pl unknown
- 2011-07-28 US US13/812,269 patent/US20130156765A1/en not_active Abandoned
- 2011-07-28 CN CN201180046311.6A patent/CN103154036B/zh active Active
- 2011-07-28 HU HUE11813204A patent/HUE044869T2/hu unknown
- 2011-07-28 ES ES11813204T patent/ES2719623T3/es active Active
- 2011-07-28 AU AU2011282579A patent/AU2011282579B2/en active Active
- 2011-07-28 KR KR1020207023918A patent/KR20200111213A/ko not_active Ceased
- 2011-07-28 AR ARP110102729A patent/AR082404A1/es active IP Right Grant
- 2011-07-28 TW TW105116005A patent/TWI588157B/zh active
- 2011-07-28 CN CN201610238182.5A patent/CN105820256A/zh active Pending
- 2011-07-28 KR KR1020187012379A patent/KR102148265B1/ko active Active
- 2011-07-28 KR KR1020137002321A patent/KR102066996B1/ko active Active
- 2011-07-28 BR BR112013002074-1A patent/BR112013002074B1/pt active IP Right Grant
- 2011-07-28 SI SI201131710T patent/SI2598533T1/sl unknown
- 2011-07-28 CA CA2902942A patent/CA2902942C/en active Active
- 2011-07-28 TW TW100126848A patent/TWI542597B/zh active
- 2011-07-28 JP JP2013521984A patent/JP5826270B2/ja active Active
- 2011-07-28 CA CA2804512A patent/CA2804512C/en active Active
- 2011-07-28 MX MX2013001148A patent/MX347343B/es active IP Right Grant
- 2011-07-28 TR TR2019/06652T patent/TR201906652T4/tr unknown
- 2011-07-28 MX MX2016009799A patent/MX368531B/es unknown
- 2011-07-28 EP EP11813204.2A patent/EP2598533B1/en active Active
- 2011-07-28 EP EP19157219.7A patent/EP3543257A1/en active Pending
2013
- 2013-01-27 IL IL224427A patent/IL224427A/en active IP Right Grant
- 2013-01-28 MX MX2019012016A patent/MX2019012016A/es unknown
2015
- 2015-07-03 JP JP2015134698A patent/JP6225142B2/ja active Active
2017
- 2017-07-05 US US15/642,175 patent/US11117940B2/en active Active
- 2017-09-28 IL IL254796A patent/IL254796B/en active IP Right Grant
2019
- 2019-04-05 HR HRP20190652TT patent/HRP20190652T1/hr unknown
- 2019-08-15 IL IL268724A patent/IL268724B/en unknown
2021
- 2021-08-12 US US17/400,367 patent/US12084482B2/en active Active
2024
- 2024-08-05 US US18/794,852 patent/US20240383951A1/en active Pending

Also Published As

Publication number	Publication date
TWI588157B (zh)	2017-06-21
TWI542597B (zh)	2016-07-21
KR20130043171A (ko)	2013-04-29
TR201906652T4 (tr)	2019-05-21
CA2902942C (en)	2020-12-22
JP2013543483A (ja)	2013-12-05
US20240383951A1 (en)	2024-11-21
MX347343B (es)	2017-04-21
KR20200111213A (ko)	2020-09-28
CA2804512A1 (en)	2012-02-02
CN103154036A (zh)	2013-06-12
IL224427A (en)	2017-10-31
TW201706313A (zh)	2017-02-16
JP2015227346A (ja)	2015-12-17
IL254796A0 (en)	2017-12-31
AU2011282579A1 (en)	2013-01-24
EP2598533B1 (en)	2019-02-20
CA2902942A1 (en)	2012-02-02
CA2804512C (en)	2015-11-24
MX368531B (es)	2019-10-07
KR102148265B1 (ko)	2020-08-26
WO2012016073A2 (en)	2012-02-02
JP5826270B2 (ja)	2015-12-02
US20130156765A1 (en)	2013-06-20
AU2011282579B2 (en)	2014-10-23
MX2013001148A (es)	2014-02-27
ES2719623T3 (es)	2019-07-11
PL2598533T3 (pl)	2019-07-31
US12084482B2 (en)	2024-09-10
DK2598533T3 (en)	2019-04-23
KR20180050429A (ko)	2018-05-14
TW201207104A (en)	2012-02-16
IL254796B (en)	2019-09-26
IL268724B (en)	2022-05-01
CN105820256A (zh)	2016-08-03
US20220056087A1 (en)	2022-02-24
HUE044869T2 (hu)	2019-12-30
WO2012016073A3 (en)	2012-08-09
CN103154036B (zh)	2016-05-11
KR102066996B1 (ko)	2020-01-17
AR082404A1 (es)	2012-12-05
MX2019012016A (es)	2019-11-11
HRP20190652T1 (hr)	2019-05-31
EP3543257A1 (en)	2019-09-25
BR112013002074A2 (pt)	2016-05-24
EP2598533A4 (en)	2015-08-05
JP6225142B2 (ja)	2017-11-01
BR112013002074B1 (pt)	2021-09-14
IL268724A (en)	2019-10-31
EP2598533A2 (en)	2013-06-05
US11117940B2 (en)	2021-09-14
US20180002388A1 (en)	2018-01-04
SI2598533T1 (sl)	2019-05-31

Publication	Publication Date	Title
IL268724B (en)	2022-05-01	Proteins are fused from natural human protein fragments to create ordered immunoglobulin multimer fc preparations
IL256879A (en)	2018-03-29	Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin fc preparations with enhanced complement binding
ZA201208906B (en)	2014-05-28	Humanised antigen binding proteins to myostatin6
IL216680A (en)	2017-11-30	Growth hormone fusion protein containing human growth hormone attached to an elongated polypeptide
EP2970490A4 (en)	2017-04-26	Antibodies to mica and micb proteins
RS55609B1 (sr)	2017-06-30	Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
EP2723380A4 (en)	2015-10-07	HYBRID LIGHT CHAIN IMMUNOGLOBULIN PROTEINS AND METHODS OF USE THEREOF
EP2539473A4 (en)	2013-03-13	MODIFIED PROTEINS AND METHODS OF MAKING AND USING THE SAME
PH12013502378A1 (en)	2014-01-06	Fc RECEPTOR BINDING PROTEINS
EP3000825A4 (en)	2017-02-08	Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein
EP2629788A4 (en)	2014-03-19	USE OF HUMAN SERUM ALBUMIN TO REDUCE THE ANTIGENICITY OF THERAPEUTIC PROTEINS
PT2919801T (pt)	2020-07-30	Composição farmacêutica estável da proteína de fusão tnfr:fc etanercept
HK1213775A1 (zh)	2016-07-15	噬菌體的融合蛋白作爲澱粉樣蛋白結合劑的用途
EP2797629A4 (en)	2015-09-30	AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
IL223665B (en)	2020-01-30	Human antibodies to human cytomegalovirus gb (cmv) protein
IL264257A (en)	2019-02-28	Fusion proteins of human protein fragments to create ordered multimeric fc immunoglobulin preparations with improved fc receptor binding
HK1178935A1 (zh)	2013-09-19	含增強免疫應答的融合蛋白的方法和組合物
IL241417A0 (en)	2015-11-30	Modification and new compositions of human scartoglobin proteins
EP2383336A4 (en)	2013-01-23	PEPTIDE CAPABLE OF BINDING TO AN IMMUNOGLOBULIN
EP2623512A4 (en)	2014-03-26	PEPTIDE THAT COULD BIND TO IMMUNOGLOBULIN
RS56559B1 (sr)	2018-02-28	Upotreba p3 fuzionih proteina bakteriofaga kao vezujućih agenasa amiloida